Cupid Secures Rs. 16.23 Crore Orders For Male Condoms From Central Medical Services Society

Cupid Limited, a leading manufacturer, has garnered orders totalling Rs. 16.23 crores from the Central Medical Services Society (CMSS) for the supply of male condoms, the company informed in a press statement on Monday. Established as a Central Procurement Agency (CPA) with Cabinet approval, CMSS plays a crucial role in streamlining drug procurement and distribution for the Department of Health & Family Welfare (DoHFW), under the Ministry of Health and Family Welfare, Government of India.

Cupid successfully secured two separate orders for male condoms from CMSS, amounting to Rs. 9.65 crores and Rs. 6.58 crores, respectively. The company aims to fulfil these orders by April 2024, as disclosed in the exchange filing on January 8, 2024.

Aditya Halwasiya, Managing Director of Cupid , expressed excitement about this significant allocation from the Government of India, highlighting the company’s unwavering commitment to supporting the government’s vision of promoting a safe and healthy lifestyle for all citizens. He stated, “This collaboration underscores the importance of ensuring access to vital resources for the well-being of the community at large.”

Furthermore, Halwasiya emphasised Cupid Limited’s alignment with the Government of India’s initiative to “Help India Play Safe.” He mentioned that Cupid Limited’s proposed production capacity expansion in the next 18-24 months positions the company well for future orders from the government.

This development not only strengthens Cupid Limited’s partnership with the Government of India but also reflects the company’s dedication to contributing to public health initiatives. The successful execution of these orders is anticipated to play a vital role in advancing the accessibility of essential resources within the healthcare sector.

Related Posts

Piyush Goyal meets pharma industry leaders to discuss R&D, competitiveness boost

New Delhi: Union Commerce and Industry Minister Piyush Goyal has discussed strategies to boost competitiveness and strengthen research and development activities with the business representatives of the pharmaceutical industry. “Had…

Senores Pharma to Buy Two Teva ANDAs

Mumbai, August 14, 2025 — Senores Pharmaceuticals will acquire two abbreviated new drug applications (ANDAs) from Teva Pharmaceuticals USA. The deal is Senores’ third US move in six months, underscoring…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Piyush Goyal meets pharma industry leaders to discuss R&D, competitiveness boost

Piyush Goyal meets pharma industry leaders to discuss R&D, competitiveness boost

Senores Pharma to Buy Two Teva ANDAs

Senores Pharma to Buy Two Teva ANDAs

Lab-grown rabies antibodies show promise as cheaper, safer alternative

Lab-grown rabies antibodies show promise as cheaper, safer alternative

Lilly launches Mounjaro KwikPen in India

Lilly launches Mounjaro KwikPen in India